With the development of PARP inhibitors for treatment of cancer patients with an altered BRCA1 or BRCA2 gene, there is an urgent need to ensure that there are appropriate strategies for identifying mutation carriers whilst balancing the increased demand for and cost of cancer genetics services. The gene discussed is BRCA2; the disease is cancer.